Patients with psoriasis who were treated with apremilast (Otezla) lost an average of nearly five pounds over a 52-week period, according to results of a pooled analysis published in the Journal of the American Academy of Dermatology.
DERM Topics
Recent Posts
- Number of PAs in US Increases 28% in Four Years
- DEF Announces Travel Stipend for East Coast Biologic & Small Molecule Free CME Bootcamp
- Skin Tests May Predict Food Allergies, Eczema
- Second-Generation Melanoma Vaccine Shows Long-Term Benefits
- As Many as 7 in 10 Patients Report Significant Mental Health Impact from Eczema